More than 80% of Patients with Diffuse Large B-cell Lymphoma Responded to Novel Therapeutic, according to the Results of a Preclinical Trial

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

Related Keywords

United States ,California ,China ,San Diego ,American ,Xiaolin Zhang ,Davida Litman ,American Society Of Hematology ,Dizal Pharmaceuticals China ,Dizal Pharmaceuticals ,Pharmacy Times ,American Society ,Annual Meeting ,